Science Corporation’s brain tech is worth $3.5 billion after new funding

rifanmuazin - Thursday, November 19, 2026 | 13:10
Finance Poetry
Science Corporation’s brain tech is worth $3.5 billion after new funding

Science Corporation, the pioneering medical technology startup founded in 2021 by former Neuralink president Max Hodak, has successfully closed a massive $400 million Series D funding round. According to a company blog post and information shared by a source familiar with the transaction, the substantial new capital injection values the biotechnology enterprise at $3.5 billion.

The financing round attracted a prominent syndicate of venture capital firms, healthcare institutions, and specialized investors. Backers in the round included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. This robust financial backing underscores growing investor confidence in the commercial and clinical potential of bio-electronic medical devices and advanced neural interfaces.

Max Hodak’s journey in biotechnology began during his undergraduate years, when he actively pursued opportunities in academic research by talking his way into a graduate neuroscience laboratory. Since those early days, his career has remained steadfastly focused on decoding the complexities of the nervous system. Alongside a team of multidisciplinary experts, Hodak launched Science Corporation with the core mission of leveraging cutting-edge technological advancements to deeply understand and directly interact with the human brain.

The company’s flagship product, PRIMA, represents a major milestone in the field of bio-electronic medicine. PRIMA is a sophisticated wearable and implantable microchip designed to help individuals suffering from age-related macular degeneration recover a meaningful degree of functional vision. The device has already achieved regulatory approval in Europe and is currently commercially available for patients in Germany, while simultaneously undergoing rigorous clinical trials for additional ophthalmic indications.

The clinical footprint of the PRIMA system expanded further when Max Hodak took the stage at TechCrunch Disrupt to announce that the device is now being actively trialed for patients suffering from Stargardt disease, another devastating, blindness-causing genetic condition. By moving beyond age-related macular degeneration, Science Corporation hopes to demonstrate the versatility of the PRIMA platform in addressing a broader spectrum of degenerative retinal diseases that currently lack effective long-term treatments.

Science Corporation’s brain tech is worth $3.5 billion after new funding

With the newly secured $400 million in Series D capital, Science Corporation is setting its sights firmly on the United States market. The startup aims to bring the PRIMA system to American patients by leveraging the U.S. Food and Drug Administration’s Humanitarian Device Exemption pathway. This specialized regulatory mechanism is designed to encourage the development of medical devices intended to benefit patients in the treatment or diagnosis of rare conditions that affect small populations.

Science Corporation has successfully persuaded the FDA that advanced macular degeneration occurring in both eyes is sufficiently uncommon to qualify for this designation, paving the way for potential U.S. availability for individuals suffering from severe bilateral vision loss.

Despite the immediate commercial and clinical focus on restoring sight through retinal implants, Science Corporation’s broader, long-term ambition remains deeply rooted in establishing a direct, high-bandwidth connection to the human brain. The company’s foundational purpose involves developing an innovative bio-hybrid sensor built from a sophisticated combination of cultured biological neurons and silicon architecture.

To turn this ambitious vision into a clinical reality, the startup is currently designing its initial human trials for the neural sensor in close collaboration with Dr. Murat Günel, a prominent professor of neurosurgery at Yale University. Dr. Günel previously discussed the partnership with TechCrunch, noting that the bio-hybrid technology holds profound potential to provide novel treatments for Parkinson’s disease, alongside a wide range of other severe brain injuries and neurological illnesses.

As Science Corporation deploys its $400 million war chest, the company stands at a crucial intersection between clinical translation and advanced technological research. By simultaneously pushing forward with commercializing its vision-restoring retinal chips in international markets, seeking U.S. regulatory pathways, and laying the groundwork for revolutionary human brain-computer interface trials, the startup continues to solidify its position as a major force in the evolving landscape of modern medical technology and neuroscience.

Source : Finance Poetry
Author : rifanmuazin
Editor : Finance Poetry Editorial Team